BGM Group Ltd.

What they do

BGM itself has no material business operations and does not own equity in its Chinese operating entities; it controls Gansu QLS (the VIE) and its subsidiaries through contractual VIE Agreements and consolidates them under U.S. GAAP. The PRC operations, run through Gansu QLS, its 100%-owned subsidiary Jiuquan Ahan Biotechnology, and PRC subsidiaries of a Hong Kong holding company, make pharmaceutical preparations and health-related products. One named product, Ahan Antibacterial Paste, is described as a disinfection paste made from a mixture of 11 traditional Chinese herbal ingredients.

Revenue drivers

• Pharmaceutical preparations (Gansu QLS / VIE) — The registrant is classified under SIC code Pharmaceutical Preparations and operates in China through the VIE Gansu QLS and its subsidiaries; the filing identifies this VIE structure as the source of substantially all of the Company's business operations, though the excerpt does not break out segment-level revenue.
• Ahan Antibacterial Paste — A disinfection paste made from a mixture of 11 traditional Chinese herbal ingredients, produced by Jiuquan Ahan Biotechnology Co., Ltd., which is 100% owned by Gansu QLS.
• PRC trading subsidiaries — Qilian International Trading (Chengdu) Co., Ltd. and Qilian Shan International Trade (Hainan) Co., Ltd. are PRC limited liability companies wholly owned by Qilian International (Hong Kong) Holdings Limited, positioned as the group's trading entities; the excerpt does not quantify their revenue.

Recent performance

Revenue fell from $57.1M in 2021 to $64.9M in 2022 and then to $46.5M in 2023, $25.1M in 2024 and a trough, with fiscal 2025 (ended September 30, 2025) recovering to $37.9M. Net income turned negative in 2023 at -$7.8M and deteriorated to -$1.4M in 2024 and -$19.9M in fiscal 2025. Diluted EPS was negative in each of the last three years: -$1.08 (2023), -$0.20 (2024) and -$0.18 (2025). Operating cash flow swung from positive $544,238 in 2024 to -$2.4M in 2025, after several years of small positive figures. At September 30, 2025, total assets were $433.8M against total liabilities of $41.9M, with shareholders' equity of $390.9M and cash and equivalents of $9.8M.

Strategy

The filing lists Item 5, Operating and Financial Review and Prospects, and Item 4, Information on the Company, as the sections covering the business and its direction, but the provided excerpt contains only the table of contents and introductory pages, so specific strategic initiatives are not described in the source material. What is stated is structural: BGM operates in China through the VIE Gansu QLS and its subsidiaries, with U.S.-listed Class A ordinary shares under the symbol BGM. No capital-raising, product-development or acquisition plans can be cited from the excerpt provided.

Risks

• VIE structure — BGM is a Cayman holding company with no material operations that does not own any equity in Gansu QLS and relies on contractual VIE Agreements to consolidate and receive the economic benefits of the Chinese operating entities.
• Deteriorating profitability — Net losses widened to -$19.9M in fiscal 2025 from -$1.4M in 2024 and -$7.8M in 2023, alongside negative diluted EPS in each of those years.
• Negative operating cash flow — Operating cash flow swung to -$2.4M in fiscal 2025 after $544,238 in 2024, while cash and equivalents stood at only $9.8M against total liabilities of $41.9M at September 30, 2025.
• Revenue base not yet recovered — Revenue in fiscal 2025 of $37.9M remains well below the 2022 peak of $64.9M despite rebounding from the $25.1M recorded in 2024.

Outlook

The excerpt provided does not include management's forward-looking outlook, guidance or targets for fiscal 2026, so no outlook can be summarized from the source material. The most recent reported data point to a business with recovering revenue but widening losses and negative operating cash flow in fiscal 2025.